Biomimetic inventions face the same challenge as any other innovation in bringing a product or process from concept to market. Despite a sea of innovative Biomimetic ideas, Biomimetic concepts largely struggle to achieve commercialisation of these ideas for social benefit¹. It is also well recognized that working over interfaces between various organisations and multidisciplinary sectors is a consistent challenge on accelerating new innovative technologies through to commercialisation. Swedish Biomimetics 3000® is addressing this opportunity by operating under its innovation accelerating model, V²IO®, (Virtual, Venture, Intersectional, Organisation) which provides a wide portfolio of business support, including design of structural development programs financial, technical, legal and management functions, all through a 24 hour hands on “intersectional means”.
The support by “intersectional means” refers to transferring the invention to a commercial technology including in an early stage having brought in cutting edge and industrial partner support in its fine tuning of the technological and commercialisation development processes. The V²IO® model is built upon maximized outsourced (virtual)resources to professional global organisations for flexibility, deliverability and established capabilities. The innovation accelerating model operates as an “Intersectional catalyst” with an especially enhanced ability to integrate multiple disciplines/cultures and their corresponding global challenges in order to have the concepts, ideas and innovations materialize to a physical reality. The operating model is a novel pathway to accelerate innovative technologies to commercialisation by establishing a “consortium of skills” made available to the program as a support to the inventor, driving the development pathway towards highly focused and defined applications to the marketplace in the shortest time.
The consortium approach accelerates the development process of the applications through the provision of intellectual support, ensuring that the development approaches adopted are continuously focused keenly upon the end application goal and generating the necessary records of development to meet the most stringent needs of later commercialisation partners, which are required to take the technology to full commercialisation in the market place.
Experience has shown that by defining measurable objectives and setting realistic schedules, building joint teams in a consortium and, above all, anticipating and mitigating risks and opportunities – in short, a highly structured development approach - improves the chances of rapid commercialisation success. Motivation and commitment from the consortium, with the added synergy of knowledge and experience, achieves cooperative results and tangible, lasting successes. In doing so, Swedish Biomimetics 3000® is taking on tasks normally not addressed by traditional Venture Capital Groups, Bioincubators, Spin-outs, or Governments.
The V²IO® model is conceived as a much needed complement not only for technology advancements by traditional funding bodies but also as a successful alternative for established Corporations to find innovations outside their own organizations². Swedish Biomimetics 3000® has the vision, commitment and the necessary virtual global network to actively drive scientific, financial and commercial growth initiatives, thereby accelerating technology portfolios.
It provides a novel alternative to current funding vehicles and technological advancement programs in encouraging the research community to maintain and focus its central scientific role in the development consortium.
¹National Geographic Magazine, April 2008, “ For all the power of Biomimetics Paradigm- -has led to surprisingly few mass produced products and arguably only one house hold - world, Velcro, which was invented in 1948…”
² Harvard Business Review, June 2007, “ Buyer´s Guide to the Innovationn Bazar” By Satish Nambisan, and Mohanbir Sawhnew